MX2016006815A - Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). - Google Patents

Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).

Info

Publication number
MX2016006815A
MX2016006815A MX2016006815A MX2016006815A MX2016006815A MX 2016006815 A MX2016006815 A MX 2016006815A MX 2016006815 A MX2016006815 A MX 2016006815A MX 2016006815 A MX2016006815 A MX 2016006815A MX 2016006815 A MX2016006815 A MX 2016006815A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
family kinase
aminopyridine derivatives
tam family
tam
Prior art date
Application number
MX2016006815A
Other languages
English (en)
Inventor
Zhang Zaihui
Original Assignee
Signalchem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signalchem Lifesciences Corp filed Critical Signalchem Lifesciences Corp
Publication of MX2016006815A publication Critical patent/MX2016006815A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

En este documento se proporcionan derivados de aminopiridina y composiciones farmacéuticas que son útiles como inhibidores de cinasas de la familia TAM.
MX2016006815A 2013-11-27 2014-11-26 Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). MX2016006815A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361909828P 2013-11-27 2013-11-27
US201361909830P 2013-11-27 2013-11-27
PCT/US2014/067709 WO2015081257A2 (en) 2013-11-27 2014-11-26 Aminopyridine derivatives as tam family kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2016006815A true MX2016006815A (es) 2016-12-02

Family

ID=52146717

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006815A MX2016006815A (es) 2013-11-27 2014-11-26 Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
MX2020005181A MX2020005181A (es) 2013-11-27 2016-05-25 Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020005181A MX2020005181A (es) 2013-11-27 2016-05-25 Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).

Country Status (11)

Country Link
US (4) US10233176B2 (es)
EP (1) EP3074390B1 (es)
JP (1) JP6496731B2 (es)
KR (1) KR102398473B1 (es)
CN (2) CN105764514B (es)
AU (1) AU2014354711B2 (es)
BR (1) BR112016012146B1 (es)
CA (1) CA2930324C (es)
IL (1) IL245660B (es)
MX (2) MX2016006815A (es)
WO (1) WO2015081257A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
AU2018396142A1 (en) 2017-12-26 2020-07-16 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
WO2020010210A1 (en) * 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
KR20210061356A (ko) * 2018-09-18 2021-05-27 시그널켐 라이프사이언시즈 코포레이션 혈액암 치료를 위한 조합요법
JP2022516401A (ja) 2018-11-30 2022-02-28 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
BR112022011651A2 (pt) 2019-12-17 2022-08-23 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
MX2022007841A (es) 2019-12-23 2022-07-19 Kymera Therapeutics Inc Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
CA3171258A1 (en) 2020-03-19 2021-09-23 Nan JI Mdm2 degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CN112707898A (zh) * 2020-12-21 2021-04-27 徐新杰 一种杂芳基取代的吡嗪衍生物及其应用
WO2022165436A1 (en) 2021-02-01 2022-08-04 Signalchem Lifesciences Corporation Use of the axl inhibitor slc-391 as antiviral therapeutic agent

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621503C (en) 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
CA2646701A1 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
EP1900727A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
PT2114955E (pt) 2006-12-29 2013-04-18 Rigel Pharmaceuticals Inc Triazoles substituídos com arilo bicíclico em ponte ou heteroarilo bicíclico em ponte úteis como inibidores de axl
CN101622246B (zh) 2006-12-29 2015-09-30 里格尔制药公司 可用作axl抑制剂的多环杂芳基取代的三唑
EP2484679B1 (en) 2006-12-29 2016-09-28 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
CA2946305C (en) 2006-12-29 2019-09-17 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008128072A2 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2703653A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives -083
SI2205592T1 (sl) 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji
WO2009099982A1 (en) * 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
ES2391373T3 (es) 2008-04-16 2012-11-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Derivados de quinoleína como inhibidores de la cinasa AXL
SI2328888T1 (sl) 2008-07-09 2013-03-29 Rigel Pharmaceuticals, Inc. Premoščeni biciklični heteroaril substituirani triazoli, uporabni kot inhibitorji Axl
EP2326641B1 (en) * 2008-07-09 2014-09-03 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
US8546433B2 (en) 2009-01-16 2013-10-01 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
CN102307875A (zh) 2009-02-09 2012-01-04 苏伯俭股份有限公司 吡咯并嘧啶基axl激酶抑制剂
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
WO2011095196A1 (en) 2010-02-05 2011-08-11 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
US9096584B2 (en) * 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
WO2012087938A1 (en) * 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
US8901120B2 (en) 2011-04-01 2014-12-02 University Of Utah Research Foundation Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase
UA114900C2 (uk) 2011-11-14 2017-08-28 Ігніта, Інк. Похідні урацилу як інгібітори axl і c-met-кінази
PT2810937T (pt) 2012-01-31 2017-03-03 Daiichi Sankyo Co Ltd Derivado de piridona
WO2013162061A1 (ja) 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
JP6284949B2 (ja) 2013-01-02 2018-02-28 ハー・ルンドベック・アクチエゼルスカベット Ｌｒｒｋ２阻害剤としてのアミノピリジン誘導化合物

Also Published As

Publication number Publication date
AU2014354711B2 (en) 2018-10-25
WO2015081257A3 (en) 2015-07-02
IL245660A0 (en) 2016-06-30
WO2015081257A2 (en) 2015-06-04
AU2014354711A1 (en) 2016-06-02
EP3074390A2 (en) 2016-10-05
CN110156770A (zh) 2019-08-23
US10233176B2 (en) 2019-03-19
KR102398473B1 (ko) 2022-05-16
CA2930324A1 (en) 2015-06-04
CA2930324C (en) 2022-01-18
US11034686B2 (en) 2021-06-15
BR112016012146A2 (pt) 2017-08-08
US11034685B2 (en) 2021-06-15
US20200299288A1 (en) 2020-09-24
MX2020005181A (es) 2020-08-17
JP6496731B2 (ja) 2019-04-03
CN105764514A (zh) 2016-07-13
BR112016012146B1 (pt) 2022-11-01
EP3074390B1 (en) 2020-07-08
KR20160091358A (ko) 2016-08-02
BR112016012146A8 (pt) 2018-01-30
IL245660B (en) 2020-01-30
CN110156770B (zh) 2022-10-04
US20200299287A1 (en) 2020-09-24
US10723725B2 (en) 2020-07-28
JP2017501981A (ja) 2017-01-19
US20190152965A1 (en) 2019-05-23
CN105764514B (zh) 2019-07-12
US20170022189A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
MX2020005181A (es) Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
PH12019500176A1 (en) Heterocyclic compounds and ther uses
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12016500739A1 (en) Inhibitors of the fibrolast growth factor receptor
IL240290B (en) History of pyridazinone-amide and pharmaceutical preparations containing them
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
IL240291A0 (en) History of pyridazinone and pharmaceutical preparations containing them
EP3082817A4 (en) Compositions for drug administration
TN2015000411A1 (en) Ceftolozane antibiotic compositions
MX2015012416A (es) Compuestos heterociclicos y sus usos.
EP2986291A4 (en) COMPOUNDS DERIVED FROM 4-PYRIDONE AND USES THEREOF AS INHIBITORS OF HIV INTEGRASE
IN2013MU03641A (es)
EP3049389A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
IL243227B (en) History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them
HK1205107A1 (en) Imidazolone derivatives, pharmaceutical compositions and uses thereof
MX2015008486A (es) Composiciones y metodos para tratar infecciones bacterianas.
EP3049077A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
IL238851A0 (en) The history of pyrrolidine, pharmaceutical preparations and their uses
MX2015016603A (es) Composiciones de corticosteroides.
IL239873B (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
IL240292A0 (en) History of quinazoline and pharmaceutical preparations containing them
MY180947A (en) Ceftolozane antibiotic compositions

Legal Events

Date Code Title Description
FG Grant or registration